Mouse Anti-DNAJB1 Recombinant Antibody (CBFYH-0131) (CBMAB-H0994-FY)

Zhang, Z., Zhang, X., Wu, X., Zhang, Y., Lu, J., & Li, D. (2022). Sirt1 Attenuates Astrocyte Activation Via Modulating Dnajb1 and Chaperone-Mediated Autophagy after Closed Head Injury. Cerebral Cortex.

Kim, S. S., Kycia, I., Karski, M., Ma, R. K., Bordt, E. A., Kwan, J., ... & Vakili, K. (2022). DNAJB1-PRKACA in HEK293T cells induces LINC00473 overexpression that depends on PKA signaling. PloS one, 17(2), e0263829.

Vyas, M., Hechtman, J. F., Zhang, Y., Benayed, R., Yavas, A., Askan, G., ... & Basturk, O. (2020). DNAJB1-PRKACA fusions occur in oncocytic pancreatic and biliary neoplasms and are not specific for fibrolamellar hepatocellular carcinoma. Modern Pathology, 33(4), 648-656.

Lu, T. W., Aoto, P. C., Weng, J. H., Nielsen, C., Cash, J. N., Hall, J., ... & Taylor, S. S. (2020). Structural analyses of the PKA RIIβ holoenzyme containing the oncogenic DnaJB1-PKAc fusion protein reveal protomer asymmetry and fusion-induced allosteric perturbations in fibrolamellar hepatocellular carcinoma. PLoS biology, 18(12), e3001018.

Tomasini, M. D., Wang, Y., Karamafrooz, A., Li, G., Beuming, T., Gao, J., ... & Simon, S. M. (2018). Conformational landscape of the PRKACA-DNAJB1 chimeric kinase, the driver for fibrolamellar hepatocellular carcinoma. Scientific reports, 8(1), 1-11.

Silva, G., Marins, M., Chaichanasak, N., Yoon, Y., Fachin, A. L., Pinhanelli, V. C., ... & Baek, S. J. (2018). Trans-chalcone increases p53 activity via DNAJB1/HSP40 induction and CRM1 inhibition. PLoS One, 13(8), e0202263.

Graham, R. P., Lackner, C., Terracciano, L., González‐Cantú, Y., Maleszewski, J. J., Greipp, P. T., ... & Torbenson, M. S. (2018). Fibrolamellar carcinoma in the Carney complex: PRKAR1A loss instead of the classic DNAJB1‐PRKACA fusion. Hepatology, 68(4), 1441-1447.

Engelholm, L. H., Riaz, A., Serra, D., Dagnæs-Hansen, F., Johansen, J. V., Santoni-Rugiu, E., ... & Frödin, M. (2017). CRISPR/Cas9 engineering of adult mouse liver demonstrates that the Dnajb1–Prkaca gene fusion is sufficient to induce tumors resembling fibrolamellar hepatocellular carcinoma. Gastroenterology, 153(6), 1662-1673.

Kastenhuber, E. R., Lalazar, G., Houlihan, S. L., Tschaharganeh, D. F., Baslan, T., Chen, C. C., ... & Lowe, S. W. (2017). DNAJB1–PRKACA fusion kinase interacts with β-catenin and the liver regenerative response to drive fibrolamellar hepatocellular carcinoma. Proceedings of the National Academy of Sciences, 114(50), 13076-13084.

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme-Linked Immunospot (ELISpot)
Proteogenomics
Other Protocols